Codiak Biosciences
The leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines.
Launch date
Employees
Market cap
€797k
Enterprise valuation
€9m (Public information from Apr 2023)
Share price
$0.057 CDAK
San Francisco California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$31.0m | Series A | ||
$61.0m | Series B | ||
$76.5m | Series C | ||
N/A | $82.5m | IPO | |
N/A | $66.4m | Post IPO Equity | |
* | N/A | $20.0m | Post IPO Equity |
N/A | N/A | Bankruptcy | |
* | N/A | Acquisition | |
Total Funding | €153m |
Recent News about Codiak Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.